The two commercially available prophylactic vaccines that target human papilloma virus type 16 (HPV16) and HPV18 have proved extremely effective. Here, Schiller and Lowy summarize the characteristics of both the vaccines and HPV that have contributed to this success and speculate on whether or not this information could be used to direct the development of vaccines against other sexually transmitted viruses.
- John T. Schiller
- Douglas R. Lowy